MedPath

Prospective Cohort Study Evaluating the Prognosis of Patients with Resectable Large 3 and 4 Type Gastric Cancer and Clinical Phase II trial Evaluating the Safety and Benefit of Perioperative Chemotherapy for Resectable Large 3 and 4 Type Gastric Cancer

Phase 2
Recruiting
Conditions
gastric cancer
Registration Number
JPRN-UMIN000013491
Lead Sponsor
Department of Surgical Oncology, Kanazawa Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1. administration contraindication of TS-1, CDDP, DOC, PAC 2. severe complications such as paralytic ileus, bowel obstruction, interstitial pneumonitis or pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure and hepatic failure etc. 3. massive ascites or pleural effusion 4. severe watery diarrhea 5. schronous double cancer 6. pregnancy or lactation 7. physician concludes that the patient's participation in this trial is inappropriate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The proportion of the patients who completed the treatment
Secondary Outcome Measures
NameTimeMethod
The proportion of adverse events, DFS, and OS.
© Copyright 2025. All Rights Reserved by MedPath